- Home
- BRAG vs XFOR Comparison
BRAG vs XFOR Comparison
Compare BRAG & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRAG
- XFOR
- Stock Information
- Founded
- BRAG 2018
- XFOR 2014
- Country
- BRAG Canada
- XFOR United States
- Employees
- BRAG N/A
- XFOR N/A
- Industry
- BRAG Office Equipment/Supplies/Services
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BRAG Technology
- XFOR Health Care
- Exchange
- BRAG Nasdaq
- XFOR Nasdaq
- Market Cap
- BRAG 117.8M
- XFOR 118.4M
- IPO Year
- BRAG N/A
- XFOR N/A
- Fundamental
- Price
- BRAG $3.73
- XFOR $0.19
- Analyst Decision
- BRAG Strong Buy
- XFOR Strong Buy
- Analyst Count
- BRAG 3
- XFOR 3
- Target Price
- BRAG $7.33
- XFOR $2.83
- AVG Volume (30 Days)
- BRAG 55.0K
- XFOR 1.9M
- Earning Date
- BRAG 05-08-2025
- XFOR 05-06-2025
- Dividend Yield
- BRAG N/A
- XFOR N/A
- EPS Growth
- BRAG N/A
- XFOR N/A
- EPS
- BRAG N/A
- XFOR N/A
- Revenue
- BRAG $105,602,029.00
- XFOR $2,557,000.00
- Revenue This Year
- BRAG $16.92
- XFOR $355.69
- Revenue Next Year
- BRAG $9.87
- XFOR $140.28
- P/E Ratio
- BRAG N/A
- XFOR N/A
- Revenue Growth
- BRAG 9.07
- XFOR N/A
- 52 Week Low
- BRAG $2.86
- XFOR $0.19
- 52 Week High
- BRAG $6.70
- XFOR $1.39
- Technical
- Relative Strength Index (RSI)
- BRAG 42.28
- XFOR 29.03
- Support Level
- BRAG $3.50
- XFOR $0.20
- Resistance Level
- BRAG $3.75
- XFOR $0.22
- Average True Range (ATR)
- BRAG 0.23
- XFOR 0.03
- MACD
- BRAG 0.00
- XFOR 0.00
- Stochastic Oscillator
- BRAG 39.51
- XFOR 4.84
About BRAG Bragg Gaming Group Inc.
Bragg Gaming Group Inc is predominantly a B2B online gaming technology platform and casino content aggregator. The Company's proprietary studios offer high-performing, data-driven casino gaming titles from in-house brands Wild Streak, Spin, Atomic Slot Lab, Indigo Magic and Oryx Gaming. It offers a full range of games including slot games, table games, card games, video bingo, scratch card games, virtual sports, and live dealer games which are featured on the company's PAM platform and also available for use on other gaming platforms offered by third parties. Geographically, the company generates a majority of its revenue from the Netherlands and the rest from Curacao, Malta, United States, Croatia, and other regions.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.